| Code | CSB-RA011661MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to APG-808, targeting the interleukin-4 receptor (IL4R). IL4R is a type I transmembrane protein that serves as a component of receptor complexes for both IL-4 and IL-13, two critical cytokines involved in type 2 immune responses. Upon ligand binding, IL4R initiates JAK-STAT signaling pathways that regulate allergic inflammation, IgE production, and alternative macrophage activation. Dysregulated IL4R signaling plays a central role in the pathogenesis of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and other type 2 inflammatory conditions.
APG-808 represents a therapeutic antibody designed to block IL4R signaling by preventing both IL-4 and IL-13 from engaging their respective receptor complexes. This biosimilar antibody provides researchers with a valuable tool for investigating IL4R-mediated pathways, studying type 2 inflammation mechanisms, and exploring therapeutic interventions in allergic and inflammatory disease models. It supports studies examining immune cell differentiation, cytokine signaling networks, and the molecular basis of atopic disorders.
There are currently no reviews for this product.